Consistent with the primary cohort, patients receiving pCR in the external validation cohort also showed statistical differences in tumor size, Ki67 index, HER2 status, and HR status as compared with non-pCR patients (all the p-values <0.05). The gene discussed is ERBB2; the disease is neoplasm.